▲ +31.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Armata Pharmaceuticals in the last 3 months. The average price target is $7.33, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 31.42% upside from the last price of $5.58.
The current consensus among 4 polled investment analysts is to buy stock in Armata Pharmaceuticals.
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.